Why big players are pouring millions in THIS biotech stock

Stock trades near $11 after steep 2025 decline. [https://invezz.com/wp-content/uploads/2021/06/Best-Biotech-Stocks-to-Buy-in-June-2021-Feature-Image.jpg] Intellia Therapeutics (NASDAQ: NTLA) has been getting a lot of buzz lately among investors who follow the biotech space. The company uses CRISPR gene editing technology to develop treatments, and while their stock has been all over the place historically, something’s changed in 2025 that has people taking notice. Analysts and big institutional investors have been piling into the stock recently, which usually means they’re seeing something promising in the company’s pipeline or business prospects. Cathie Wood’s ARK Invest ETFs became the latest player to invest around $4 million for 349,930 Intellia shares. RENEWED MARKET OPTIMISM DESPITE STOCK PRICE VOLATILITY Intellia’s stock has had a rough stretch over the past year, dropping from above $30 to about $11.36 by late August 2025. The near-term picture doesn’t look much better, with some expecting another 10% slide in September. Even so, analysts are still positive on the longer-term story, pointing more to Intellia’s research progress and drug pipeline than to short-term trading swings. Recently, Intellia has been getting more attention. Partnerships, some movement…